3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase NA
1
Phase 3
1
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Dermatologic
2
Breast
2
Sarcoma
1
Head & Neck
1
CNS
1
Conditions
Melanoma
426
Carcinoma, Non-Small-Cell Lung
92
Neoplasm Metastasis
69
Neoplasms
60
Carcinoma, Renal Cell
54
Lymphoma, T-Cell, Cutaneous
52
Ovarian Neoplasms
46
Squamous Cell Carcinoma of Head and Neck
42
Breast Neoplasms
40
Colorectal Neoplasms
38
Stomach Neoplasms
37
Skin Neoplasms
35
Lymphoma
32
Uveal Melanoma
31
Mycosis Fungoides
31
Carcinoma, Merkel Cell
31
Triple Negative Breast Neoplasms
29
Lung Neoplasms
29
Sezary Syndrome
28
Lymphoma, Non-Hodgkin
28
Lymphoma, Follicular
27
Hodgkin Disease
27
Pancreatic Neoplasms
26
Uterine Cervical Neoplasms
25
Sarcoma
25
Lymphoma, Large B-Cell, Diffuse
24
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, B-Cell, Marginal Zone
23
Carcinoma, Hepatocellular
23
Lymphoma, Mantle-Cell
22
Interventions
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Drug-Related Side Effects and Adverse Reactions
×
Dermatologic
×
Clear all
NCT06120712
2025-12-23
MIZAR-002
Shanghai Juncell Therapeutics
Phase 1/2
Completed
18 enrolled
NCT03638375
2023-12-12
ACTME
Leiden University Medical Center
Phase 1/2
Unknown
34 enrolled